Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression. (January 2021)

• Record Type: Journal Article
• Authors: Mishra, Sandeep K.; Hidau, Mahendra Kumar; Rai, Shivika
• Is Part Of: Neurochemistry international. Volume 142(2021)
• Publication Date: 2021-01
• Subjects: Chronic unpredictable stress -- Memantine -- Memory impairment -- Mitochondrial dysfunction -- Neuroprotection; Neurochemistry -- Periodicals; Neurochemistry -- Periodicals; Neurochimie -- Périodiques; Neurochemistry; Periodicals; 612.804205
• DOI: 10.1016/j.neuint.2020.104932
• Languages: English
• ISSNs: 0197-0186

Abstract

Abstract: Mitochondrial and cognitive dysfunctions have long been associated with major depressive disorders (MDDs). Studies have shown that Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, possesses an antidepressant-like effect. Hence, the NMDA receptor can be a better therapeutic target for MDD. Therefore, the present study was designed to study the impact of Memantine on mitochondrial functional status and depression-like symptoms in the chronic unpredictable stress (CUS) model of depression. CUS for 28 days resulted in depression-like symptoms (as indicated by increased immobility time in the forced swim test) and a decline in the spatial learning and retention memory in the Morris water maze (MWM) test, which was prevented by Memantine (10 mg/kg/day) treatment. We observed elevated plasma corticosterone (CORT) levels, microdialysates glutamate concentration, and synaptosomal calcium (Ca 2+ ) ion levels after 28 days of CUS. Memantine treatment prevented only increased plasma CORT and synaptosomal Ca 2+ ion levels. Memantine treatment also restored CUS induced increase in oxidative stress parameters [increased neuronal nitric oxide synthase (nNOS) expression, nitric oxide (NO) levels, lipid peroxidation (LPO) and superoxide dismutase (SOD) activity], decrease in mitochondrial electron transport chain (ETC) enzymes activity and mitochondrial membrane potential (MMP). CUS also reduced the expression of cell survival genes, cyclic-AMP response element-binding protein (CREB), and brain-derived nerve growth factor (BDNF), which was reversed by treatment with Memantine. CUS, however, caused a non-significant decrease in the hippocampal adenosine triphosphate (ATP) levels and a non-significant increase in the expression of pro-apoptotic genes, Caspase 3, and the number of TUNEL positive cells, indicating that hippocampal mitochondrial dysfunction caused due to CUS was not severe enough to affect overall energy production, mitochondrial integrity, and cellular apoptosis status. Thus, Memantine treatment exerts an antidepressant-like effect by preventing CUS induced excitotoxicity, oxidative stress, and enhancing CUS induced decrease in mitochondrial functioning and expression of cell survival genes via upregulation of stress-responsive CREB/BDNF signaling. Graphical abstract: Image 1 Highlights: Memantine prevented Chronic unpredictable stress (CUS) induced depression-like symptoms, including decrease in spatial learning and retention memory. Memantine decreased CUS induced rise in plasma corticosterone (CORT) and synaptosomal Ca 2+ ion level, without affecting the raised glutamate levels. Memantine treatment prevented CUS induced mitochondrial oxidative stress and mitochondrial dysfunction. Memantine treatment prevented CUS-induced reduction in the expression of cell survival genes. Memantine treatment does not affect the hippocampal ATP levels and the apoptotic status of the hippocampal cells.